Advertisement
Advertisement
U.S. markets open in 37 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BetterLife Pharma Inc. (BETR.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
0.18000.0000 (0.00%)
At close: 03:11PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1800
Open0.0000
Bid0.1500 x N/A
Ask0.1800 x N/A
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume46,952
Market Cap15.372M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-0.1610
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for BETR.CN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      BetterLife Files Comprehensive Patent for BETR-001 and Other LSD Derivatives

      VANCOUVER, British Columbia, Sept. 27, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce filing of a PCT patent application along with a U.S. application for lysergic acid diethylamide (“LSD”) derivatives, including 2-bromo-LSD. The applications cover compositions of these derivat

    • GlobeNewswire

      BetterLife and Collaborators to Submit Key Joint Research Publication

      VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that BetterLife is working with its collaborators on a key research publication on BETR-001, its proprietary 2-bromo-LSD, and plans to submit it for review to a prestigious peer-reviewed journ

    • GlobeNewswire

      BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects

      VANCOUVER, British Columbia, Aug. 24, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders. A recent study, published in Experimental Neurology, has provided some new evidence that LSD has nootropic effects which are believed to be driven by neuroplasticity promotion. Researchers found that LSD increased

    Advertisement
    Advertisement